The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Recordati SpA's Revenue for the
three
months ended in Mar. 2026 was €713 Mil. Recordati SpA's average Accounts Receivable for the
three
months ended in Mar. 2026 was €615 Mil.
Hence, Recordati SpA's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.16.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Recordati SpA Receivables Turnover Related Terms
Recordati SpA Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:REC vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a Receivables Turnover of 1.16 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Recordati SpA and its competitors. According to the industry distribution chart, Recordati SpA ranks #562 out of 946 companies in the Drug Manufacturers industry, placing it in the top 59.4%.
Is Recordati SpA's Receivables Turnover too high?
Recordati SpA's current Receivables Turnover is 1.16. The Drug Manufacturers industry median Receivables Turnover is 5.07. Recordati SpA's value of 1.16 is 77.1% below this industry median. Based on the distribution chart, Recordati SpA ranks #562 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #562 out of 946 companies for Receivables Turnover. This places Recordati SpA in the lower half of its industry. The industry median Receivables Turnover is 5.07. Recordati SpA's value of 1.16 is 77.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current Receivables Turnover of 1.16 is 77.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Receivables Turnover is 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.77, compared to a current price of €51.40 — trading 15.4% below its estimated fair value. The current Receivables Turnover is 1.16 and 77.1% below the Drug Manufacturers industry median of 5.07. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Receivables Turnover is 1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.40 is trading 15.4% below its estimated GF Value™ of €60.77.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
Receivables Turnover: 1.16
GF Value™: €60.77 vs. price of €51.40 (15.4% below fair value)
Industry Position: 77.1% below the Drug Manufacturers median (#562 of 946)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
